Tracer Development

The radio pharmacy closely interacts with the pre-clinical imaging devision for the development and validation of novel radiotracers in the field of oncology and neurosciences.

The research involves a proof-of-concept program on monitoring (tumor-associated) protease activity by radiolabeled tracers. Furthermore the development of tracers for monitoring the tumor microenvironment and specifically cell death are envisaged.

A last research track involves the development of tracers to visualize phosphodisesterase (PDE) activity and other brain targets.